Navigation Links
InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
Date:11/4/2009

BRISBANE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.

"IPF is a rapidly and uniformly fatal disease. Sadly, there are no medicines approved for the approximately 100,000 Americans who suffer from this terrible disease," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. "InterMune has dedicated almost ten years to the development of new medicines for patients with IPF. We are very proud to have submitted the first NDA ever submitted to the FDA for a medicine to treat IPF patients."

About Pirfenidone

Preclinical and in-vitro evidence had shown that pirfenidone has both anti-fibrotic and anti-inflammatory effects. Results from three adequate and well-controlled Phase 3 studies have shown evidence of a treatment effect in IPF patients and the compound has been safe and generally well tolerated, with side effects including photosensitivity rash and gastrointestinal symptoms.

InterMune licensed pirfenidone from Marnac, Inc. and its co-licensor, KDL GmbH, in 2002 and in 2007 purchased from Marnac and KDL the rights to sell the compound in the United States, Europe and other territories except in Japan, Taiwan and South Korea where rights to the molecule were licensed by Marnac and KDL to Shionogi & Co. Ltd. of Japan. In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi in that country.

<
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... LAUSANNE , Suisse, October 1, 2014 /PRNewswire/ ... génomique clinique et dans le domaine de l,analyse ... a lancé aujourd,hui une solution de diagnostic in ... d,exécuter une analyse complète de la mucoviscidose dans ... d,identifier et de caractériser tous les types de ...
(Date:9/30/2014)... report analyzes the worldwide markets for Enteral Feeding Devices in ... Nasogastric Tubes, and Others. The report provides separate ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. The report profiles 38 companies ...
(Date:9/30/2014)... , Sept. 30, 2014 MiMedx Group, Inc. ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and ... Koob , Ph.D., Chief Scientific Officer, will present at ... will present on Tuesday, October 7, 2014, at 5:00PM ...
Breaking Medicine Technology:Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19MiMedx to Present at the Stem Cell Meeting on the Mesa 2
... in Glasgow,have devised a new method of attacking ... of Clinical Investigation* today,(Thursday). , A team of ... mice a chemical that caused cancer cells to ... they were,carrying. The chemical kick started a gene ...
... Development Plans - , ,OTTAWA, Canada – March ... specializing in developing,advanced products related to High Density ... of,the Phase I/II Clinical Trial of its lead ... of dyslipidemia and heart,disease. , ,Results showed, to ...
Cached Medicine Technology:Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 2Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 3Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3
(Date:10/1/2014)... the human eye, the brain of a rat and ... technology, says a QUT leading robotics researcher. , ... says the new study uses new computer algorithms to ... or tunnels. , "This is a very Frankenstein type ... halves of a thing together because we,re taking the ...
(Date:10/1/2014)... 2014 Patients with increased inflammation, including those ... increased risk of depression. For example, a 6-month ... C virus infection causes depression in approximately 30% ... commonly known as fish oil, have a long ... of heart disease and reducing triglyceride levels. These ...
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
(Date:10/1/2014)... October 01, 2014 Marriagelifeinsurance.com has ... life insurance for retired couples. , Senior citizens ... financial security for their loved ones. A joint policy ... insured persons pass away. , Life insurance can ... life insurance can even be purchased online, as the ...
(Date:10/1/2014)... Hills, CA (PRWEB) October 01, 2014 ... internationally-franchised Fit Body Boot Camp fitness boot camps, he’s ... selling personal training , with sold out business summits, ... stint as marketing consultant to a recent Spike TV ... Keuilian says that now is the time for personal ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3
... WLAN provides Palmer with critical access control features and ... support for bandwidth-intensive applications, ... Conference -- Colubris Networks, the leading global provider of,intelligent ... that Palmer College of Chiropractic, the largest,chiropractic college in ...
... Late breaking results from the SPIRIT III trial, presented ... Cardiovascular Research Foundation, show that after 12 months, there ... as heart attacks, deaths from cardiac causes or repeat ... blockage after using a Xience V everolimus-eluting coronary stent ...
... at Baylor College of Medicine boosted its sequencing capabilities ... Sequencer FLX Systems from 454 Life Sciences, a Roche ... Human Genome Sequencing Center will be in a unique ... ranging from the deciphering of new genomes to the ...
... Oct. 23 Immunosyn,Corporation (OTC Bulletin Board: IMYN) has ... Chief Executive Officer, President and,board member. "I am ... and help,shape the company,s success. I believe we have ... of people who suffer from painful and,debilitating diseases," says ...
... small financial incentives to health workers in low-income countries may ... malaria in young children, according to a study published on ... by an expert panel as one of eight of the ... research and policy and will be presented at the launch ...
... 23 Mylan Inc. (NYSE: MYL ),today ... Inc. have,entered into a patent license and settlement ... Extended-release (ER),Tablets, the generic version of GSK,s Paxil ... Paroxetine HCl ER Tablets will be dismissed with,prejudice. ...
Cached Medicine News:Health News:Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses 2Health News:Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses 3Health News:Fewer adverse cardiac events at one year 2Health News:Baylor College of Medicine increases fleet of Roche Genome Sequencer FLX Systems to 10 instruments 2Health News:Immunosyn Corporation Names Stephen Ferrone as CEO 2Health News:Financial incentives may hold key to cutting child malaria deaths 2Health News:Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline 2
... EUB-2000 is a compact system capable ... This unit features intuitive operation, high ... membrane style keyboard incorporates an alphanumeric ... mode changes, and toggle keys for ...
... advanced circuit designs optimized for efficiency and ... an engineering philosophy that directs the development ... at the same time, providing seamless integration ... is extraordinary performance in image quality and ...
... flexible, and fast, the HI VISION ... edge technologies with user-oriented operation for ... SONO MR package consists of advanced ... including HI COMPOUND multi-angle spatial compounding, ...
... The Pentax EG-3630U incorporates a 2.4mm ... It features an all electronic convex linear ... electronic beam focus for improved lateral resolution, ... deeper ultrasound imaging. The color & ...
Medicine Products: